Trendlines says its most valuable portfolio company is Stimatix
Stimatix sold its assets in Nov 2014 to a B Braun subsidiary; Trendlines' current holding of 28.2% valued at US$42.6m
Add BT as a preferred sourceSingapore
CATALIST-LISTED The Trendlines Group - an Israel and Singapore-based incubator of medtech and agritech startups - has disclosed that an asset it described as its "Most Valuable Portfolio Company" is Stimatix GI.
In a statement on Monday, Trendlines said that Stimatix, which develops medical products to aid patients with intestinal blockage, sold its assets in November 2014 to a subsidiary of German medical device company B Braun Group. B Braun will market Stimatix's ostomy products internationally from mid-2018.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Are Keppel’s dividends truly unsustainable – or just misunderstood?
UOB aims to double wealth income to at least S$2.5 billion by 2030; Q1 profit slips 4%
Sony, Singapore’s GIC to pay almost US$4 billion for Bieber, Neil Young catalogue
